Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesCancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753139

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753139

Neoantigen Cancer Vaccines

PUBLISHED:
PAGES: 380 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Neoantigen Cancer Vaccines Market to Reach US$79.2 Million by 2030

The global market for Neoantigen Cancer Vaccines estimated at US$26.1 Million in the year 2024, is expected to reach US$79.2 Million by 2030, growing at a CAGR of 20.3% over the analysis period 2024-2030. Personalized Neo-Antigen Vaccine, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$52.5 Million by the end of the analysis period. Growth in the Off-the Shelf Neoantigen Vaccine segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.1 Million While China is Forecast to Grow at 27.6% CAGR

The Neoantigen Cancer Vaccines market in the U.S. is estimated at US$7.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.9 Million by the year 2030 trailing a CAGR of 27.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.0% and 18.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.0% CAGR.

Global Neoantigen Cancer Vaccines Market - Key Trends & Drivers Summarized

Why Are Neoantigen Cancer Vaccines Reshaping Oncology Therapeutics?

Neoantigen cancer vaccines represent a groundbreaking advancement in precision oncology, offering highly personalized therapeutic options tailored to the unique genetic makeup of a patient’s tumor. Unlike traditional cancer vaccines that target shared tumor antigens, neoantigen vaccines are derived from patient-specific tumor mutations that are not present in healthy cells, minimizing the risk of off-target effects and enhancing immunogenic specificity. This approach enables the immune system to recognize and attack cancer cells more effectively, improving the chances of long-term remission and durable immune responses.

The emergence of next-generation sequencing (NGS) and bioinformatics has made it possible to rapidly identify and prioritize patient-specific neoantigens within days, allowing for the development of bespoke vaccines that are tailored to individual tumor profiles. This level of personalization is driving a major paradigm shift in cancer treatment-particularly for melanoma, non-small cell lung cancer, colorectal cancer, and head and neck cancers-where traditional therapies often face resistance or limited efficacy. As clinical trials continue to validate the safety and immunogenicity of neoantigen vaccines, they are gaining traction as a complementary or standalone therapeutic platform in modern oncology.

What Scientific and Technological Advancements Are Driving Product Innovation?

The development of neoantigen cancer vaccines is being accelerated by a convergence of computational biology, genomic analytics, and immunoengineering. Machine learning algorithms are now used to predict which tumor-derived mutations will most likely bind to a patient’s HLA molecules and elicit a strong cytotoxic T-cell response. This in silico screening dramatically reduces the time and cost involved in identifying viable vaccine candidates, making large-scale clinical deployment increasingly feasible.

On the delivery side, innovation in vaccine platforms is enhancing immune activation and durability. Technologies such as lipid nanoparticles, mRNA, dendritic cell-based delivery, and synthetic long peptides are being employed to improve antigen presentation and overcome immunosuppressive tumor microenvironments. Additionally, adjuvant systems and combination therapies-especially with checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 blockers-are proving effective in boosting the immune system’s response to neoantigens. These synergies are creating multi-modal cancer therapies that can be dynamically adapted to tumor evolution, marking a significant leap forward in immunotherapeutic precision.

How Are Clinical Adoption and End-Use Scenarios Evolving?

Neoantigen vaccines are gradually moving from experimental use to structured clinical pathways, particularly within early-phase oncology trials and personalized medicine programs. Their adoption is currently centered around high-mutation-load cancers such as melanoma and certain types of lung and gastrointestinal cancers, where a broad array of neoantigens increases vaccine efficacy. These vaccines are being integrated into neoadjuvant, adjuvant, and recurrence-prevention strategies, and are increasingly being studied in combination with immunotherapies, radiation, and chemotherapy for synergistic benefit.

Hospitals, cancer research institutes, and specialty oncology centers are the primary end-use channels, often working in collaboration with biotech firms to conduct patient profiling, manufacturing, and post-treatment immune monitoring. This co-development ecosystem is enabling more streamlined workflows from biopsy to vaccine synthesis to clinical deployment. As the infrastructure for personalized oncology expands-including genomic testing capabilities, biobanking, and AI-driven analysis platforms-neoantigen vaccines are poised to become more scalable and clinically routine.

What Factors Are Driving Growth in the Neoantigen Cancer Vaccines Market?

The growth in the neoantigen cancer vaccines market is driven by several interlinked factors related to technological progress, precision medicine uptake, and oncology treatment innovation. A major growth catalyst is the rising demand for personalized therapies that minimize toxicity and maximize tumor-specific immune targeting. Neoantigen vaccines directly respond to this need, offering unprecedented specificity and a favorable safety profile.

End-use expansion across high-burden cancer types and integration into multimodal treatment regimens are accelerating clinical and commercial interest. The maturation of enabling technologies-especially NGS, AI-based epitope prediction, and mRNA vaccine platforms-is reducing production timelines and improving scalability. Regulatory agencies are also showing increasing openness to individualized therapeutics, with some neoantigen programs gaining fast-track and orphan drug designations, which further facilitate clinical translation.

Additionally, increased venture capital investment and biopharma collaborations are fueling R&D momentum. Academic-industry partnerships are helping build decentralized manufacturing capabilities, while government-sponsored precision medicine initiatives are embedding personalized immunotherapy within national cancer care frameworks. As clinical evidence continues to mount and manufacturing processes become more agile, neoantigen cancer vaccines are set to become a cornerstone of next-generation oncology treatment paradigms.

SCOPE OF STUDY:

The report analyzes the Neoantigen Cancer Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Personalized Neo-Antigen Vaccine, Off-the Shelf Neoantigen Vaccine); Administration Route (Intravenous, Intramuscular, Transdermal, Other Administration Routes); Application (Melanoma, Brain Cancer, Gastrointestinal, Lung, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Agenus Inc.
  • BioNTech SE
  • Candel Therapeutics
  • Genelux Corporation
  • Geneos Therapeutics
  • GlaxoSmithKline plc (GSK)
  • Grey Wolf Therapeutics
  • HiFiBiO Therapeutics
  • Immunovant, Inc.
  • Moderna, Inc.
  • Nouscom AG
  • Personalis, Inc.
  • Recombio
  • SpliceBio
  • Transgene S.A.
  • Vaccibody AS
  • Vaximm AG
  • Vaxine Pty Ltd
  • ViroTarg
  • Y-mAbs Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP35412

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neoantigen Cancer Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in Tumor Genomics and Next-Gen Sequencing Drive Development of Personalized Neoantigen Vaccines
    • OEM Investment in mRNA and DNA Vaccine Platforms Strengthens Pipeline of Neoantigen-Based Therapies
    • Growing Demand for Individualized Immunotherapy Supports Expansion of Custom Tumor-Specific Vaccines
    • Rising Cancer Incidence and Unmet Clinical Need Accelerate Regulatory Support for Neoantigen Trials
    • Push for Tumor-Agnostic Therapies Enhances Scope of Neoantigen Vaccines in Hard-to-Treat Cancers
    • Growing Use of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors Enhances Efficacy
    • OEM Focus on AI and Bioinformatics Tools Improves Neoantigen Prediction and Immunogenicity Scoring
    • Expansion of Global Cancer Vaccine Clinical Trials Drives Geographic Diversification of Neoantigen Research
    • OEM Development of Off-the-Shelf Neoantigen Libraries Targets Common Cancer Mutations in Semi-Personalized Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neoantigen Cancer Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neoantigen Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neoantigen Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Personalized Neo-Antigen Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Personalized Neo-Antigen Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Personalized Neo-Antigen Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Off-the Shelf Neoantigen Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Off-the Shelf Neoantigen Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Off-the Shelf Neoantigen Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Brain Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Brain Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Brain Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Gastrointestinal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Neoantigen Cancer Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Neoantigen Cancer Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Neoantigen Cancer Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Neoantigen Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Neoantigen Cancer Vaccines by Product - Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Neoantigen Cancer Vaccines by Product - Percentage Breakdown of Value Sales for Personalized Neo-Antigen Vaccine and Off-the Shelf Neoantigen Vaccine for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Neoantigen Cancer Vaccines by Application - Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Neoantigen Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Lung, Other Applications, Melanoma, Brain Cancer and Gastrointestinal for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Neoantigen Cancer Vaccines by Administration Route - Intravenous, Intramuscular, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Neoantigen Cancer Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intravenous, Intramuscular, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!